(Q38513816)

3 September 2017

1 reference

title

The new therapeutical scenario of Hodgkin lymphoma (English)

1 reference

3 September 2017

A Stathis

1

1 reference

3 September 2017

A Younes

series ordinal

2

1 reference

3 September 2017

publication date

2 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

26

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2026-2033

1 reference

3 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

The biology of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Assignment of the human CD30 (Ki-1) gene to 1p36

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

The TNF receptor family member CD30 is not essential for negative selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Treatment of Hodgkin lymphoma: a 50-year perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Early-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Innate protection from graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Brentuximab Vedotin (SGN-35).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Brentuximab vedotin in systemic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV256

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV256

1 reference

3 September 2017

1 reference